Financials in USD. Standardized financial statements.
A compact view of how Ultragenyx Pharmaceutical Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $673.00M | $560.23M | $434.25M | $363.33M | $351.41M | $271.03M | $103.71M | $51.49M | $2.61M | $133,000 |
| Revenue Growth? | +20.1% | +29.0% | +19.5% | +3.4% | +29.7% | +161.3% | +101.4% | +1871.5% | +1863.9% | 0.0% |
| Cost of Revenue? | $109.00M | $76.73M | $45.21M | $28.32M | $16.01M | $6.13M | $9.01M | $1.15M | $1,000 | $183.20M |
| Gross Profit? | $564.00M | $483.50M | $389.04M | $335.01M | $335.40M | $264.90M | $94.71M | $50.35M | $2.61M | -$183.07M |
| Gross Margin? | +83.8% | +86.3% | +89.6% | +92.2% | +95.4% | +97.7% | +91.3% | +97.8% | +100.0% | -137647.4% |
| Operating Expenses? | $1.10B | $1.02B | $958.25M | $983.93M | $717.13M | $595.02M | $518.88M | $421.72M | $331.55M | $248.14M |
| Operating Income? | -$535.00M | -$535.97M | -$569.21M | -$648.92M | -$381.74M | -$330.12M | -$424.17M | -$371.37M | -$328.94M | -$248.01M |
| EBITDA? | -$500.00M | -$469.00M | -$516.45M | -$640.49M | -$410.32M | -$139.81M | -$389.77M | -$177.56M | -$312.51M | -$244.58M |
| Income Before Tax | -$571.00M | -$567.59M | -$608.46M | -$701.73M | -$452.98M | -$185.36M | -$399.44M | -$197.10M | -$318.34M | -$245.84M |
| Income Tax Expense | $4.00M | $1.60M | -$1.82M | $5.70M | $1.04M | $1.21M | $3.28M | $514,000 | -$16.20M | $35,000 |
| Net Income? | -$575.00M | -$569.18M | -$606.64M | -$707.42M | -$454.02M | -$186.57M | -$402.73M | -$197.61M | -$302.14M | -$245.87M |
| EPS? | $-5.83 | $-6.29 | $-8.25 | $-10.12 | $-6.70 | $-3.07 | $-7.12 | $-3.97 | $-7.12 | $-6.21 |
| Diluted EPS? | $-5.83 | $-6.29 | $-8.25 | $-10.12 | $-6.70 | $-3.07 | $-7.12 | $-3.97 | $-7.12 | $-6.21 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality